Paeds Vivas · neurology-neurodisability-and-neuromuscular
Developmental regression and neurodegeneration — branching viva
Branching viva on developmental regression and neurodegeneration: recognising regression as a red flag, distinguishing true progressive regression from plateau and static loss, grouping the causes by bedside pattern and tempo, deploying a tiered neuro-investigation anchored on the developmental history, brain MRI, sleep EEG and genomic sequencing, and never accepting a degenerative label until the treatable causes - autoimmune encephalitis, epileptic encephalopathies, GLUT1 deficiency, cerebral adrenoleukodystrophy - have been actively excluded.
On this page
Study tools
Target exams
Opening branch — the regressing adolescent
A previously well fourteen-year-old presents over ten days with insomnia, agitation, hallucinations, a seizure, and orofacial dyskinesia, with a fluctuating conscious level. The candidate must first recognise this as developmental regression in its subacute form - loss of previously acquired cognitive and behavioural function - and distinguish it from a primary psychiatric disorder. The candidate states that the combination of psychiatric onset, seizures, a movement disorder, and altered consciousness is the phenotype of autoimmune encephalitis, a treatable mimic of neurodegeneration, and that the cardinal error is dismissing the early phase as psychiatric. [3]
The examiner probes the framework. The candidate gives the Graus diagnostic approach, which permits a diagnosis of probable autoimmune encephalitis on the phenotype - subacute onset of psychiatric symptoms, seizures, a movement disorder, autonomic instability, and a decreased level of consciousness - supported by EEG, CSF, or imaging, before the antibody panel confirms it. The teaching point is that the framework exists so that empirical immunotherapy is justified while the panel returns, because the outcome is better the earlier treatment begins. [3] [4]
References5ShowHide
- [1]Moeschler JB, Shevell M Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics, 2014.PMID 25157020
- [2]Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol, 2010.PMID 21154482
- [3]Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016.PMID 26906964
- [4]Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm, 2021.PMID 34301820
- [5]Stefanatos G. Changing perspectives on Landau-Kleffner syndrome. Clin Neuropsychol, 2011.PMID 21955111